Orphenadrine CitrateExtended-release Tablets, 100 mg | Orphenadrine Citrate

13:12 EDT 23rd October 2014 | BioPortfolio
Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Rx only

Orphenadrine citrate is the citrate salt of orphenadrine (2-dimethylaminoethyl 2-methyl-benzhydryl ether citrate). It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol. Each orphenadrine citrate tablet contains 100 mg orphenadrine citrate, USP. Orphenadrine citrate tablets also contain ethylcellulose NF, povidone USP, lactose monohydrate NF, and magnesium stearate NF.

The mode of therapeutic action has not been clearly identified, but may be related to its analgesic properties. Orphenadrine citrate also possesses anticholinergic actions.

Orphenadrine citrate is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculo-skeletal conditions. The mode of action of the drug has not been clearly identified, but may be related to its analgesic properties. Orphenadrine citrate does not directly relax tense skeletal muscles in man.

Contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardiospasm (megaesophagus) and myasthenia gravis. Contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.

Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine citrate may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly.

Safe use of orphenadrine citrate has not been established with respect to adverse effects upon fetal development. Therefore, orphenadrine citrate should be used in women of childbearing potential and particularly during early pregnancy only when in the judgement of the physician the potential benefits outweigh the possible hazards.

Safety and effectiveness in children have not been established; therefore, this drug is not recommended for use in the pediatric age group.

Confusion, anxiety and tremors have been reported in a few patients receiving propoxyphene and orphenadrine concomitantly. As these symptoms may be simply due to an additive effect, reduction of dosage and/or discontinuation of one or both agents is recommended in such cases.

Orphenadrine citrate should be used with caution in patients with tachycardia, cardiac decompensation, coronary insufficiency, or cardiac arrhythmias.

Safety of continuous long-term therapy with orphenadrine has not been established. Therefore, if orphenadrine is prescribed for prolonged use, periodic monitoring of blood, urine and liver function values is recommended.

Adverse reactions of orphenadrine are mainly due to the mild anticholinergic action of orphenadrine, and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. These adverse reactions can usually be eliminated by reduction in dosage. Very rare cases of aplastic anemia associated with the use of orphenadrine tablets have been reported. No causal relationship has been established.

TABLETS: Adults-Two tablets per day; one in the morning and one in the evening.

Tablets 100 mg-Each round, white, convex tablet imprinted with "G" on one side and "2011" on the other side.

Bottles of 100 NDC 0115-2011-01Bottles of 500 NDC 0115-2011-02

Store at controlled room temperature 15° to 30°C (59° to 86°F).

Dispense in tightly-closed, light-resistant container (USP).

Manufactured by: Impax Laboratories, Inc.Hayward, California 94544

Dist. by: Global PharmaceuticalsDivision of IMPAX Laboratories, Inc.Philadelphia, PA 19124

Rev. 01/00124-02

GLOBAL

NDC 0115-2011-02

OrphenadrineCitrateExtended-Release Tablets

100 mg

Rx only

500 TABLETS

IMAGE label1.jpg

Manufacturer

H.J. Harkins Company, Inc.

Active Ingredients

Source

Drugs and Medications [707 Associated Drugs and Medications listed on BioPortfolio]

Orphenadrine citrate [Bryant Ranch Prepack]

Orphenadrine Citrate Extended-Release Tablets

Orphenadrine citrate [STAT RX USA LLC]

Orphenadrine citrate [Global Pharmaceuticals, Division of Impax Laboratories Inc.]

Orphenadrine CitrateExtended-release Tablets, 100 mg

Orphenadrine citrate [PD-Rx Pharmaceuticals, Inc.]

Orphenadrine Citrate Extended-Release Tablets

Orphenadrine citrate [GAVIS Pharmaceuticals, LLC]

Orphenadrine Citrate Extended-Release Tablets

Clinical Trials [219 Associated Clinical Trials listed on BioPortfolio]

68Ga-Citrate PET of Healthy Volunteers

This study investigates whole-body distribution kinetics of intravenously administered Gallium-69 (68Ga) citrate by positron emission tomography (PET)/computed tomography (CT). Thereafter,...

Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT

1. To compare the differences of citrate pharmacokinetics in healthy individuals and critically ill patients as well as the influential factors. 2. To validate a pharmacokinetic mo...

A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate

The purpose of this study is to perform a relative bioavailability study between two formulations of sildenafil citrate.

Traditional Clomiphene Citrate Administration vs. Stair-step Approach

The purpose of this study is to compare the length of time to achieve ovulation and pregnancy with a traditional protocol administration of clomiphene citrate versus a stair step administr...

To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.

To demonstrate a dose response for 1 mg, 5 mg and 20 mg TID oral sildenafil for the treatment of subjects with PAH.

PubMed Articles [259 Associated PubMed Articles listed on BioPortfolio]

Orphenadrine-induced convulsive status epilepticus in rats responds to the NMDA antagonist dizocilpine.

Identification of new molecular targets as well as the new models recapitulating different aspects of pathophysiology of status epilepticus (SE) in humans might prove essential for the breakthrough in...

Loss of antimicrobial effect of trisodium citrate due to 'lock' spillage from haemodialysis catheters.

Due to its reported antimicrobial effects, hypertonic citrate (46.7%) is a widely used catheter lock solution, but following instillation, citrate inevitably spills into the systemic circulation. This...

Artificial citrate operon and Vitreoscilla hemoglobin gene enhanced mineral phosphate solubilizing ability of Enterobacter hormaechei DHRSS.

Mineral phosphate solubilization by bacteria is mediated through secretion of organic acids, among which citrate is one of the most effective. To overproduce citrate in bacterial systems, an artificia...

Urinary citrate excretion in healthy children depends on age and gender.

Hypocitraturia is considered a major risk factor for calcium stone formation. However, there is no widely accepted reference database of urinary citrate excretion in children. The aim of our study was...

Ovulation induction with clomiphene citrate and metformin in women with polycystic ovary syndrome.

Polycystic ovary syndrome (PCOS) is one of the most common causes of ovulatory infertility. It is an endocrine disorders characterized by a high level of male hormones (androgens) and frequent anovula...

Search BioPortfolio:
Loading
Advertisement

Relevant Topics

Pain
Latest News Clinical Trials Research Drugs Reports Corporate
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...

Pharmacy
Latest News Clinical Trials Research Drugs Reports Corporate
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Advertisement

Drugs and Medication Quicklinks


Searches Linking to this Drug Record